Abstract 1871TiP
Background
PLATON is designed to elevate personalized therapy based on genomic tumor profiles in gastrointestinal cancer patients. Hereby, PLATON’s study-design focuses on the patient’s tumor molecular profiling. Within the network a web application will be developed to link clinical investigators and information on study sites, cancer patients and genetic alteration data, as well as available clinical trials at PLATON`s study sites.
Trial design
The PLATON Network is established as permanent open, multicenter, prospective, cohort study including biobanking and a shared platform infrastructure for associated sub-studies. The pilot-study enrolls 200 patients with signed informed consent of both sexes and ages over 18 at 40 study sites in Germany (NCT04484636), diagnosed with hepatocellular cancer (HCC), intra- and extrahepatic cholangiocellular carcinoma (CCC), gallbladder carcinoma (GBCA), pancreatic ductal adenocarcinoma (PDCA) or esophagogastric adenocarcinoma (EC/GC). At the time of enrolment, patients are in first-line therapy and no local curative therapy is available. Molecular profiling will be performed with Foundation Medicine Assays. Clinical Investigators can use the platform to search for clinical trials that match their patients’ individual molecular profile or to identify a patient eligible for a trial or other treatment options available at corresponding centers in the PLATON network. The network’s interactive web application will include a dashboard and moderated chat room to interact in a virtual Molecular Tumor Board, for example. The first patient was included on the 25th of November 2020. Up to 30th of April 2021, a total of 40 patients HCC (N = 1), CCA (N = 6), PDCA (N = 13), GBCA (N = 1) and EC/GC (N = 20) were enrolled at 12 study-sites and 52 genetic analyses were completed. All cohorts of the pilot-study are open for recruitments up to a maximum of 40 individuals per diagnostic group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut für Klinische Krebsforschung.
Funding
Roche Pharma AG.
Disclosure
All authors have declared no conflicts of interest.